Semaglutide: A Promising Ally Against Alzheimer’s?

In a groundbreaking study, researchers at Case Western Reserve School of Medicine have identified a potential new benefit of semaglutide, a widely used diabetes and weight-loss drug. According to their findings, semaglutide may significantly reduce the risk of Alzheimer’s disease in individuals with type 2 diabetes (T2D), outperforming seven other anti-diabetic medications.

Alzheimer’s disease, a devastating brain disorder that erodes memory and cognitive abilities, affects nearly 7 million Americans aged 65 and older, as reported by the Alzheimer’s Association. Alarmingly, it claims more lives annually than breast and prostate cancer combined.

Published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, the study suggests that T2D patients taking semaglutide had a markedly lower risk of developing Alzheimer’s disease. This trend was consistent across various subgroups, regardless of obesity status, gender, or age.

Semaglutide, a glucagon-like peptide receptor (GLP-1R) agonist, is the active ingredient in popular medications like Wegovy and Ozempic. It works by reducing hunger and regulating blood sugar levels in T2D patients.

Rong xu

Under the leadership of Rong Xu, a professor of biomedical informatics, the research team analyzed three years of electronic health records from nearly one million U.S. patients with T2D. Their statistical approach, which mimicked a randomized clinical trial, revealed that patients prescribed semaglutide had a significantly lower risk of Alzheimer’s compared to those on other anti-diabetic medications.

According to the CDC, Alzheimer’s disease results in approximately 120,000 deaths annually, ranking as the seventh-leading cause of death in the United States.

“This new study provides real-world evidence for semaglutide’s potential impact on Alzheimer’s disease,” Xu stated. “While preclinical research has hinted at its protective effects against neurodegeneration and neuroinflammation, our findings suggest the need for further exploration through randomized clinical trials.”

Despite these promising results, the study’s limitations prevent researchers from drawing definitive causal conclusions. Xu emphasized the importance of continued research into semaglutide’s potential as a treatment for this debilitating condition, encouraging further investigation into alternative drugs.

For more information, please contact Patty Zamora at [email protected].

More Articles

Getting licensed or staying ahead in your career can be a journey—but it doesn’t have to be overwhelming. Grab your favorite coffee or tea, take a moment to relax, and browse through our articles. Whether you’re just starting out or renewing your expertise, we’ve got tips, insights, and advice to keep you moving forward. Here’s to your success—one sip and one step at a time!

Florida Homeowners Finally Get a Break as Insurance Rates Begin to Drop

After years of soaring premiums and insurer instability, Florida’s property insurance market is finally turning a corner. Major carriers have filed 83 requests for rate decreases heading into 2026, with companies like Florida Peninsula and Patriot Select proposing cuts of 8.4% and 11.3%. Some homeowners may see relief as early as next month, signaling a long‑awaited shift toward market stability.

The Fix-and-Flip Comeback: Why 2026 Is Poised to Be a Breakout Year for Investors

Fix-and-flip investing is gearing up for one of its strongest years in a decade as 2026 approaches. With cheaper capital, more accessible funding, easing interest rates, and long-awaited increases in housing inventory, investors are finding the perfect environment to launch or scale renovation-based real estate businesses. Renovation continues to outpace new construction in cost and speed, and demand for move-in-ready homes remains high, making 2026 a powerful opportunity window for both new and experienced investors.

Falling Rents Today, Rising Pressures Tomorrow: A 2026 Rental Squeeze Is on the Horizon

After a short-lived period of relief in 2025, the U.S. rental market may be headed for a tighter, more expensive 2026. With construction starts dropping nearly 11% and completions plunging 42%, the surge of new apartments that helped lower rents is rapidly drying up. Rising costs, shrinking inventory, and a slowdown in new development point to a potential rental crunch that could leave renters facing heavier competition and higher prices across major markets next year.

The Biggest Opportunity in Real Estate Since 2008

The commercial real estate market is entering a rare reset that experts say mirrors the post‑2008 boom, creating a potential window for disciplined investors. With trillions in commercial debt coming due and property values dropping up to 40%, firms like AARE are positioning themselves to acquire assets below replacement cost—an advantage that could set the stage for significant long‑term growth.

Six for 2026: The Commercial Real Estate Shifts Already Reshaping the U.S.

Commercial real estate is entering a reinvention phase, with AI‑driven productivity, modernized office demand, experience‑focused retail, expanding industrial logistics, creative housing solutions, and sustainability‑centered design all accelerating nationwide. These six forces are shaping how investors, brokers, and future licensees will operate in a rapidly evolving U.S. market.

2026 Becomes the Turning Point: Innovation, Stability, and Upward Mobility Return

After years of economic uncertainty and cautious decision‑making, 2026 is shaping up to be the year professionals finally catch a break. AI is moving from buzzword to essential tool, capital markets are beginning to thaw, and hiring is picking up across real estate, mortgage, insurance, finance, and healthcare. With opportunity returning, many professionals are using this moment to upskill—pursuing new licenses, certifications, and cross‑industry expertise.